Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/23394
Title: The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Authors: MATTSSON, NiklasANDREASSON, UlfPERSSON, StaffanARAI, HiroyukiBATISH, Sat DevBERNARDINI, SergioBOCCHIO-CHIAVETTO, LuisellaBLANKENSTEIN, Marinus A.CARRILLO, Maria C.CHALBOT, SoniaCOART, ElsCHIASSERINI, DavideCUTLER, NealDAHLFORS, GunillaDULLER, StefanFAGAN, Anne M.FORLENZA, OrestesFRISONI, Giovanni B.GALASKO, DouglasGALIMBERTI, DanielaHAMPEL, HaraldHANDBERG, AaseHENEKA, Michael T.HERSKOVITS, Adrianna Z.HERUKKA, Sanna-KaisaHOLTZMAN, David M.HUMPEL, ChristianHYMAN, Bradley T.IQBAL, KhalidJUCKER, MathiasKAESER, Stephan A.KAISER, ElmarKAPAKI, ElisabethKIDD, DanielKLIVENYI, PeterKNUDSEN, Cindy S.KUMMER, Markus P.LUI, JamesLLADO, AlbertLEWCZUK, PiotrLI, Qiao-XinMARTINS, RalphMASTERS, ColinMCAULIFFE, JohnMERCKEN, MarcMOGHEKAR, AbhayMOLINUEVO, Jose LuisMONTINE, Thomas J.NOWATZKE, WilliamO'BRIEN, RichardOTTO, MarkusPARASKEVAS, George P.PARNETTI, LucillaPETERSEN, Ronald C.PRVULOVIC, DavidREUS, Herman P. M. deRISSMAN, Robert A.SCARPINI, ElioSTEFANI, AlessandroSOININEN, HilkkaSCHROEDER, JohannesSHAW, Leslie M.SKINNINGSRUD, AndersSKROGSTAD, BrithSPREER, AnnetteTALIB, LedaTEUNISSEN, CharlotteTROJANOWSKI, John Q.TUMANI, HayrettinUMEK, Robert M.BROECK, Bianca VanVANDERSTICHELE, HugoVECSEI, LaszloVERBEEK, Marcel M.WINDISCH, ManfredZHANG, JingZETTERBERG, HenrikBLENNOW, Kaj
Citation: ALZHEIMERS & DEMENTIA, v.7, n.4, p.386-395, 2011
Abstract: Background: The cerebrospinal fluid (CSF) biomarkers amyloid beta (A beta)-42, total-tau (T-tau), and phosphorylated-tau (P-tau) demonstrate good diagnostic accuracy for Alzheimer's disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimer's Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch-to-batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program. Methods: The program is open for laboratories using commercially available kits for A beta, T-tau, or P-tau. CSF samples (aliquots of pooled CSF) are sent for analysis several times a year from the Clinical Neurochemistry Laboratory at the Molndal campus of the University of Gothenburg, Sweden. Each round consists of three quality control samples. Results: Forty laboratories participated. Twenty-six used INNOTEST enzyme-linked immunosorbent assay kits, 14 used Luminex xMAP with the INNO-BIA AlzBio3 kit (both measure A beta-(1-42), P-tau(181P), and T-tau), and 5 used Mesa Scale Discovery with the A beta triplex (A beta N-42, A beta N-40, and A beta N-38) or T-tau kits. The total coefficients of variation between the laboratories were 13% to 36%. Five laboratories analyzed the samples six times on different occasions. Within-laboratory precisions differed considerably between biomarkers within individual laboratories. Conclusions: Measurements of CSF AD biomarkers show large between-laboratory variability, likely caused by factors related to analytical procedures and the analytical kits. Standardization of laboratory procedures and efforts by kit vendors to increase kit performance might lower variability, and will likely increase the usefulness of CSF AD biomarkers.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MPS
Departamento de Psiquiatria - FM/MPS

Artigos e Materiais de Revistas Científicas - HC/IPq
Instituto de Psiquiatria - HC/IPq

Artigos e Materiais de Revistas Científicas - LIM/27
LIM/27 - Laboratório de Neurociências


Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.